Merck to spend another $5B on stock buybacks

Merck has joined the list of drugmakers allocating billions to repurchase their own stock. The company plans to buy back up to $5 billion in shares, bringing its total share buyback program to $6.4 billion. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.